Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care
Overall survival (absolute effect size estimates based on survival rate at 12 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes overall survival (absolute effect size estimates based on survival… compared with best supportive care alone (very low certainty).
1 finding from 1 review
- HR 1.19 [0.78, 1.82]1 study · 129 participantsVery low